Real-World Treatment Study of Koselugo (Selumetinib)

Launched by ASTRAZENECA · Apr 8, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the medication Koselugo (Selumetinib) to understand how safe and effective it is for patients with Neurofibromatosis type 1, a condition that can cause tumors called neurofibromas. The trial is being conducted in South Korea as part of a commitment to gather more information about how this drug works in everyday medical settings. Researchers want to see if there are any unexpected side effects and how well the medication helps patients when prescribed by doctors in their regular practices.

To participate in the study, patients must be receiving Koselugo as approved in South Korea and need to provide written consent to take part. The trial is open to individuals aged between 3 and 18 years, and both boys and girls can join. Participants can expect to be monitored closely to gather information about their health and how they respond to the treatment. This study aims to provide valuable insights into the experiences of patients in Korea who are using this medication.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients treated with Koselugo (Selumetinib) under the approved label in South Korea
• • 2. Provision of signed and dated written informed consent by the patient or legally acceptable representative
• Exclusion Criteria:
• • 1. Patients treated with Koselugo (Selumetinib) under the approved label in South Korea
• • 2. Provision of signed and dated written informed consent by the patient or legally acceptable representative